Advertisement
Advertisement
U.S. markets close in 2 hours 29 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Certara, Inc. (CERT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
21.73-0.79 (-3.51%)
As of 01:31PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close22.52
Open22.63
Bid21.71 x 1000
Ask21.76 x 900
Day's Range21.68 - 22.81
52 Week Range16.17 - 45.48
Volume270,925
Avg. Volume536,246
Market Cap3.473B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.09
Earnings DateAug 03, 2022 - Aug 08, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CERT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Certara, Inc.
    Daily – Vickers Top Buyers & Sellers for 06/06/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    last monthArgus Research
View more
  • GlobeNewswire

    Certara Introduces New Simcyp™ Discovery Simulator for Early-Stage and Translational Drug Development

    Advances lead optimization, first-in-human dose prediction and formulation developmentPRINCETON, N.J., June 28, 2022 (GLOBE NEWSWIRE) -- Certara (Nasdaq: CERT), a global leader in biosimulation, today announced the release of Simcyp Discovery Simulator, a new software designed for scientists working in small molecule drug discovery and translational research. Derived from the industry-leading Simcyp Simulator, Simcyp Discovery increases confidence in early-stage development decisions using physi

  • GlobeNewswire

    Certara Announces New Versions of Biosimulation Software for Development of Novel Biologics

    New capabilities enhance clinical predictability for different compounds across more therapeutic areasPRINCETON, N.J., June 21, 2022 (GLOBE NEWSWIRE) -- Certara, a global leader in biosimulation, today announced the release of new versions of its Immunogenicity (IG), Immuno-oncology (IO) and Vaccine Simulators to help predict how drugs work and address key questions in the development of novel biologic therapies. “The latest versions of our simulators help tackle some of the toughest challenges

  • Motley Fool

    Certara, Inc. (CERT) Q1 2022 Earnings Call Transcript

    On the call from Certara, we have William Feehery, chief executive officer; and Andrew Schemick, chief financial officer. Earlier today, Certara released financial results for the quarter ended March 31st, 2022.

Advertisement
Advertisement